ATE175190T1 - Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten - Google Patents

Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten

Info

Publication number
ATE175190T1
ATE175190T1 AT92921435T AT92921435T ATE175190T1 AT E175190 T1 ATE175190 T1 AT E175190T1 AT 92921435 T AT92921435 T AT 92921435T AT 92921435 T AT92921435 T AT 92921435T AT E175190 T1 ATE175190 T1 AT E175190T1
Authority
AT
Austria
Prior art keywords
dimethylethyl
oxo
cyano
hexanoates
preparing
Prior art date
Application number
AT92921435T
Other languages
English (en)
Inventor
Donald Eugene Butler
Tung Van Le
Alan Millar
Thomas Norman Nanninga
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE175190T1 publication Critical patent/ATE175190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
    • C07C255/21—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
AT92921435T 1991-10-11 1992-10-05 Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten ATE175190T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/775,162 US5155251A (en) 1991-10-11 1991-10-11 Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate

Publications (1)

Publication Number Publication Date
ATE175190T1 true ATE175190T1 (de) 1999-01-15

Family

ID=25103514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92921435T ATE175190T1 (de) 1991-10-11 1992-10-05 Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten

Country Status (16)

Country Link
US (1) US5155251A (de)
EP (1) EP0643689B1 (de)
JP (2) JP3241723B2 (de)
AT (1) ATE175190T1 (de)
AU (1) AU667320B2 (de)
CA (1) CA2116973C (de)
DE (1) DE69228073T2 (de)
DK (1) DK0643689T3 (de)
ES (1) ES2129457T3 (de)
FI (1) FI941632A (de)
MX (1) MX9205824A (de)
NO (1) NO300208B1 (de)
PT (1) PT100943B (de)
SG (1) SG46599A1 (de)
WO (1) WO1993007115A1 (de)
ZA (1) ZA927793B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
JP3171931B2 (ja) * 1992-06-02 2001-06-04 高砂香料工業株式会社 （Ｒ）−（−）−４−シアノ−３−ヒドロキシ酪酸ｔ−ブチルエステル及びその製造方法
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
GB9512837D0 (en) * 1995-06-23 1995-08-23 Zeneca Ltd reduction of ketone groups
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5908953A (en) * 1996-12-18 1999-06-01 Mitsubishi Chemical Corporation Method for producing (R)-4-cyano-3-hydroxybutyric acid lower alkyl ester
JPH11171850A (ja) * 1997-12-12 1999-06-29 Kanegafuchi Chem Ind Co Ltd 酪酸エステル誘導体の製造方法
ES2284219T3 (es) 1997-12-19 2007-11-01 Pfizer Ireland Pharmaceuticals Procedimiento de sintesis de 1,3-dioles.
DE69910562T2 (de) * 1998-04-30 2004-06-17 Kaneka Corp. Verfahren zur herstellung von derivaten der 6-cyanomethyl-1,3-dioxan-4-essigsäure
PT1619191E (pt) 1998-08-05 2010-12-21 Kaneka Corp Processo de produção de derivados opticamente activos do ácido 2-[6-(hidroximetil)-1,3-dioxan-4-il]acético
KR100313668B1 (ko) * 1999-02-03 2001-11-26 박영구 (ｒ)-4-시아노-3-히드록시부티르산 에스테르의 제조방법
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
USRE39333E1 (en) 1999-06-04 2006-10-10 Kaneka Corporation Process for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
US20040063969A1 (en) * 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
AU780247B2 (en) * 1999-12-17 2005-03-10 Pfizer Science And Technology Ireland Limited A process for producing crystalline atorvastatin calcium
EP1237865B1 (de) 1999-12-17 2005-11-16 Pfizer Science and Technology Ireland Limited Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
CN100368386C (zh) * 2000-05-31 2008-02-13 中国医学科学院药物研究所 （±）对氟-2-（2-甲基-丙酰基）-4-氧-n，3-二苯基-苯丁酰胺的合成方法以及其中的中间体
CN101250133B (zh) * 2000-05-31 2010-06-09 中国医学科学院药物研究所 (±)对氟-2-(2-甲基-丙酰基)-4-氧-n，3-二苯基-苯丁酰胺的合成方法以及其中的中间体
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1724256A3 (de) 2001-01-09 2007-03-21 Warner-Lambert Company LLC Neues Verfahren zur Synthese von N-Phenyl-5-(4-Fluorphenyl)-1-(2-((2R,4R)-4-Hydroxy-6-Oxotetrahydropyran-2-Yl)Ethyl)-2-Isopropyl-4-Phenyl-1H-Pyrrol-3-Carbonsäureamid
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
CN1524073A (zh) * 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
EP1406860A1 (de) * 2001-07-06 2004-04-14 Teva Pharmaceutical Industries Limited Produkte natürlichen ursprungs mit organisch gebundenem iod
HUP0401145A3 (en) 2001-07-06 2008-08-28 Ciba Sc Holding Ag Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
CZ2004158A3 (cs) 2001-07-06 2005-01-12 Teva Pharmaceutical Industries Ltd. Syntéza a meziprodukty derivátů 3,5-dihydroxyheptanové kyseliny
WO2003011826A1 (en) 2001-07-30 2003-02-13 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
JP4765217B2 (ja) * 2001-07-30 2011-09-07 住友化学株式会社 （ｒ）−４−シアノ−３−ヒドロキシブタン酸エステルの製造法
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
AU2001284385A1 (en) * 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
KR100849880B1 (ko) * 2001-12-20 2008-08-01 주식회사 중외제약 광학활성 2-[6-(치환된 알킬)-1,3-디옥산-4-일]아세트산유도체의 신규 제조 방법
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
PL375415A1 (en) * 2002-08-06 2005-11-28 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
EP1537222B1 (de) * 2002-08-09 2011-03-09 Codexis, Inc. Enzymatische verfahren zur herstellung 4-substituierter 3-hydroxybuttersäure-derivate
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
WO2004089894A1 (en) * 2003-04-14 2004-10-21 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
JP2007500219A (ja) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CN1852894A (zh) * 2003-09-17 2006-10-25 沃尼尔·朗伯有限责任公司 [R－(R*, R*)]－2－(4－氟苯基) －β,δ－二羟基－5－(1－甲基乙基) －3－苯基－4－[(苯基氨基)羰基] －1 H－吡咯－1－庚酸的结晶形式
US7557238B2 (en) * 2003-09-18 2009-07-07 Biocon Limited Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
US7943786B2 (en) * 2003-12-29 2011-05-17 Ljubomir Antoncic Process for preparing amorphous (4R-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
FI120344B (fi) 2004-03-17 2009-09-30 Ranbaxy Lab Ltd Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
US20070225353A1 (en) * 2004-04-16 2007-09-27 Pfizer, Inc. Process for Forming Amorphous Atorvastatin
WO2005105738A2 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of atorvastatin
BRPI0513396A (pt) * 2004-07-16 2008-05-06 Lek Pharmaceuticals produtos de degradação oxidativa de atorvastatina de cálcio
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CA2578722C (en) * 2004-08-27 2010-02-02 Biocon Limited Process for atorvastatin calcium amorphous
MX2007004722A (es) * 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
CA2621506A1 (en) * 2005-09-09 2007-03-15 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate
JP2009507822A (ja) * 2005-09-09 2009-02-26 ファイザー・サイエンス・アンド・テクノロジー・アイルランド・リミテッド アトルバスタチン中間体の調製
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
WO2007057755A1 (en) 2005-11-21 2007-05-24 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
CN101528917B (zh) * 2006-10-02 2015-07-29 科德克希思公司 用于制备立体异构纯的他汀类及其合成中间体的组合物和方法
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
WO2008059366A2 (en) * 2006-11-17 2008-05-22 Pfizer Products Inc. Process for the preparation of cis-1, 3-diols from the corresponding beta-hydroxy ketones employing microbial ketone reductases
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
WO2009013633A2 (en) * 2007-07-20 2009-01-29 Actavis Group Ptc Ehf Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
ES2523404T3 (es) * 2007-08-03 2014-11-25 Pfizer Products Inc. Procedimiento de preparación de compuestos quirales
EP2075246A1 (de) 2007-12-27 2009-07-01 M. J. Institute of Research Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
GB2474687A (en) * 2009-10-23 2011-04-27 Phoenix Chemicals Ltd A continuous process for the production of (R)-6-cyano-5-hydroxy-3-oxo-hexanoic acid tert-butyl ester (and derivatives)
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2012032035A1 (en) 2010-09-09 2012-03-15 Dsm Sinochem Pharmaceuticals Netherlands B.V. Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
MX2013015272A (es) 2011-07-01 2014-04-14 Dsm Sinochem Pharm Nl Bv Cristales micronizados.
CN102766072B (zh) * 2012-08-07 2013-12-25 浙江宏元药业有限公司 一种制备阿托伐他汀钙手性侧链的方法
CN103145584B (zh) * 2013-03-05 2015-08-26 复旦大学 一种合成(3r,5r)-3,5-二羟基-6-氰基己酸酯的方法
CN106397241A (zh) * 2016-08-23 2017-02-15 杨锋 一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
CN108033899B (zh) * 2017-12-06 2020-04-10 浙江科技学院 一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4611067A (en) * 1985-01-31 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis

Also Published As

Publication number Publication date
FI941632A0 (fi) 1994-04-08
NO941280L (no) 1994-04-08
AU2764192A (en) 1993-05-03
NO300208B1 (no) 1997-04-28
FI941632A (fi) 1994-04-08
JPH07500105A (ja) 1995-01-05
CA2116973A1 (en) 1993-04-15
ZA927793B (en) 1994-04-11
DE69228073T2 (de) 1999-06-10
NO941280D0 (no) 1994-04-08
AU667320B2 (en) 1996-03-21
CA2116973C (en) 2004-09-21
JP2002030060A (ja) 2002-01-29
SG46599A1 (en) 1998-02-20
JP3429500B2 (ja) 2003-07-22
PT100943B (pt) 1999-07-30
DE69228073D1 (de) 1999-02-11
PT100943A (pt) 1993-10-29
JP3241723B2 (ja) 2001-12-25
US5155251A (en) 1992-10-13
DK0643689T3 (da) 1999-08-30
ES2129457T3 (es) 1999-06-16
EP0643689B1 (de) 1998-12-30
MX9205824A (es) 1993-04-01
EP0643689A1 (de) 1995-03-22
WO1993007115A1 (en) 1993-04-15

Similar Documents

Publication Publication Date Title
ATE175190T1 (de) Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten
DE69014396D1 (de) Verfahren zur Herstellung von permeationsbeständigen Silikonelastomer enthaltenden Mehrschichtstrukturen sowie dadurch hergestellte Artikel.
DE3885366D1 (de) Verfahren zur Herstellung von Pyrrolo-(3,4-c)pyrrolen.
DE69014707D1 (de) Verfahren zur Herstellung von CMOS-Feldeffekt-Transistoren.
DE3883408D1 (de) Verfahren zur Herstellung von Avermectinen und die verwendeten Kulturen.
ATE190050T1 (de) Verfahren zur herstellung von 2-acetyl-1-pyrrolin in verkapselter form, zwischenprodukte und endprodukt
AU4752693A (en) Strong, thin films made by double bubble process
DE68915220D1 (de) Vorrichtung zur Herstellung von Schichtstoffen.
FI940046A0 (fi) Menetelmä ruokatuotteen valmistamiseksi
DE69009614D1 (de) Verfahren zur Herstellung von (S)-gamma-Hydroxymethyl-alpha,beta-Butenolid.
EP0014958A3 (de) Verfahren zur Herstellung von 4,5-Perfluor-1,3-dioxolanen
AT371729B (de) Verfahren zur herstellung von laminaten, insbesondere skis und vakuumformvorrichtung
DE68922360D1 (de) Verfahren zur Herstellung von Metall-Polyimid-Verbundwerkstoffen.
EP0268996A3 (en) Lactonic degradation product, process for its preparation and its use
DE69013132D1 (de) Verfahren zur Herstellung von Octa-2,7-dien-1-ol.
AU2613892A (en) Process for producing dimethyl ether
DE68911603D1 (de) Verfahren zur Herstellung von 2-Pyrrolidon.
ATE80383T1 (de) Verfahren zur herstellung sulfatierter alkanoloder alkylphenol-oxethylate mit erniedrigtem gehalt an 1,4-dioxan.
DE69022014D1 (de) Verfahren zur Herstellung von S-(+)-3-Halogeno-1,2-propandiol durch Behandlung mit Mikroorganismen.
CA2064740A1 (en) Method for Enrichment of Oxygen 18 with a Laser
IE780048L (en) Treatment of whey.
JPS5390067A (en) Method of making thin film filter
KR920021069A (ko) 우뭇가사리(天草)를 이용한 청량 음료의 제조방법
JPS51130583A (en) Process for producing scp or alcohol from organic wastes, espectially kitchen wastes
DE59006458D1 (de) Verfahren zur Herstellung von cyclischen Amidinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee